These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19576342)

  • 1. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome.
    Melloni C; Alexander KP; Ou FS; LaPointe NM; Roe MT; Newby LK; Baloch K; Ho PM; Rumsfeld JS; Peterson ED
    Am J Cardiol; 2009 Jul; 104(2):175-81. PubMed ID: 19576342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
    El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
    Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of evidence-based cardiac drug therapy on mortality in patients with acute coronary syndrome: Findings from the Gulf COAST registry.
    Al-Zakwani I; Zubaid M; Alsheikh-Ali AA; Almahmeed W; Rashed W
    Cardiovasc Ther; 2018 Dec; 36(6):e12463. PubMed ID: 30079461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
    Lee HY; Cooke CE; Robertson TA
    J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between the use of 4 recommended drug categories and patient perceptions of health status following an ACS event.
    Erickson SV; Rangarajan K; Kline-Rogers EM; Smith DE; Eagle KA
    J Manag Care Pharm; 2009 Sep; 15(7):533-42. PubMed ID: 19739876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study.
    Bi Y; Gao R; Patel A; Su S; Gao W; Hu D; Huang D; Kong L; Qi W; Wu Y; Yang Y; Turnbull F;
    Am Heart J; 2009 Mar; 157(3):509-516.e1. PubMed ID: 19249422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of evidence-based cardiac medication on short- and long-term mortality in 7,567 acute coronary syndrome patients in the Gulf RACE-II registry.
    Al-Zakwani I; Sulaiman K; Al Za'abi M; Panduranga P; Al-Habib K; Asaad N; Al Motarreb A; Hersi A; Al Faleh H; Al Saif S; Almahmeed W; Amin H; Alsheikh-Ali A; Al Lawati J; Al Suwaidi J
    Int J Clin Pharmacol Ther; 2012 Jun; 50(6):418-25. PubMed ID: 22541748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome.
    Yan AT; Yan RT; Tan M; Huynh T; Soghrati K; Brunner LJ; DeYoung P; Fitchett DH; Langer A; Goodman SG;
    Am Heart J; 2007 Dec; 154(6):1108-15. PubMed ID: 18035083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age and persistent use of cardiovascular medication after acute coronary syndrome: results from medication applied and sustained over time.
    Ali RC; Melloni C; Ou FS; Schmader K; Ohman EM; Roe MT; Peterson ED; Alexander KP
    J Am Geriatr Soc; 2009 Nov; 57(11):1990-6. PubMed ID: 19754499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing prevention and guideline-concordant care in Montenegro.
    Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M
    Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes.
    Gencer B; Rodondi N; Auer R; Räber L; Klingenberg R; Nanchen D; Carballo D; Vogt P; Carballo S; Meyer P; Matter CM; Windecker S; Lüscher TF; Mach F
    Eur J Intern Med; 2015 Jan; 26(1):56-62. PubMed ID: 25582072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry.
    Wang TY; Robinson LA; Ou FS; Roe MT; Ohman EM; Gibler WB; Smith SC; Peterson ED; Becker RC
    Am Heart J; 2008 Feb; 155(2):361-8. PubMed ID: 18215609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary prevention of coronary artery disease in contemporary clinical practice.
    Jankowski P; Czarnecka D; Wolfshaut-Wolak R; Łysek R; Łukaszewska A; Bogacki P; Grodecki J; Mirek-Bryniarska E; Nessler J; Podolec P; Kawecka-Jaszcz K; Pająk A
    Cardiol J; 2015; 22(2):219-26. PubMed ID: 25299500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of use of combination evidence-based medical therapy after acute coronary syndromes on long-term outcomes.
    Lahoud R; Howe M; Krishnan SM; Zacharias S; Jackson EA
    Am J Cardiol; 2012 Jan; 109(2):159-64. PubMed ID: 22011560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study.
    Pereira M; Araújo C; Dias P; Lunet N; Subirana I; Marrugat J; Capewell S; Bennett K; Azevedo A
    Eur J Prev Cardiol; 2014 Nov; 21(11):1401-8. PubMed ID: 23787795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
    Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
    Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study.
    Eagle KA; Kline-Rogers E; Goodman SG; Gurfinkel EP; Avezum A; Flather MD; Granger CB; Erickson S; White K; Steg PG
    Am J Med; 2004 Jul; 117(2):73-81. PubMed ID: 15234641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of an educational program on the prevalence of use of antiplatelet drugs, beta blockers, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers prescribed during hospitalization and at hospital discharge in patients with coronary artery disease.
    Sanal S; Aronow WS
    J Gerontol A Biol Sci Med Sci; 2003 Nov; 58(11):1046-8. PubMed ID: 14630888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
    Vermeer NS; Bajorek BV
    J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry.
    Chiang FT; Shyu KG; Wu CJ; Mar GY; Hou CJ; Li AH; Wen MS; Lai WT; Lin SJ; Kuo CT; Kuo C; Li YH; Hwang JJ;
    J Formos Med Assoc; 2014 Nov; 113(11):794-802. PubMed ID: 24076272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.